The “tripledemic” shines a spotlight on viral interference, in which one infection can block another.

A clinical trial finds that the anticoagulant apixaban, which has been prescribed to help COVID-19 patients recover, is ineffective and in rare instances dangerous.

In flies and mice, a viral protein increases the rate of energy use by heart cells. But it’s not yet clear if the finding applies to humans.

Natural science research projects were among those promised funding by the now-collapsed crypto exchange’s “effective altruism” foundations.

The National Institute of Allergy and Infectious Diseases was not aware that the work involved a chimeric strain of SARS-CoV-2, STAT reports.

Low booster rates and immune-evading SARS-CoV-2 variants could spell bad news, experts say. 

Researchers say they’re abandoning the project in its current form—one of several that aims to induce what’s known as mucosal immunity against SARS-CoV-2.

Recent studies have lent support for a variety of hypotheses explaining the debilitating symptoms affecting millions of people after SARS-CoV-2 infection.  

This year’s awards recognize work on integrins, noninvasive prenatal screening, and COVID-19 data tracking.

The results from two large clinical trials don't support the idea that supplements of the vitamin bolster immune defenses against SARS-CoV-2.

Launched with a $172 million philanthropic donation and funds from the state of Victoria, the Melbourne-based research institute aims to construct drug discovery platforms to speed the introduction of new therapies.

The immunizations are designed to target the latest Omicron subvariants, and are only authorized for people who have already received their primary vaccinations.

The Scientist spoke with Maximilien Chaumon about his database showing how COVID-19 related lockdowns warped more 2,800 people’s perception of time.